pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›psilocybin
drug · small molecule
save

psilocybin

Phase 3updated 6mo ago
by $CMPS COMPASS Pathways plc🔗 ChEMBL
Phase 3
community read0 votes

🐶 often sniffed alongside

top 7
  • drugOral Psilocybin6 co-mentions · 6 sources
  • drug(aeruginascin + baeocystin + psilocybin)6 co-mentions · 6 sources
  • drugMYCO-0036 co-mentions · 6 sources
  • drugPsilocybin (Microneedle Patch)6 co-mentions · 6 sources
  • companyNew York University1 co-mentions · 1 sources
  • tagPsychiatry & CNS1 co-mentions · 1 sources
  • tagPain1 co-mentions · 1 sources

Small molecule drug with a maximum clinical stage of Phase 3 (across all indications), with 35 investigational indications.

indications

indications
Major DepressionObesity

targets

5-hydroxytryptamine receptor 2A

all catalysts(0)

nothing on the calendar yet

Trials studying psilocybin

  • phase2Psilocybin-Assisted Psychotherapy in Cancer Patients With Adjustment Disorderrecruitingn=87
  • phase3Redefine Study: A Study Evaluating the Efficacy, Safety, and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorderrecruitingn=300
  • phase1ADEPT Psilocybin-Assisted Therapy With DBT for Borderline Personality Disordernot yet recruitingn=18
  • phase1MLS101 Study in PMDDnot yet recruitingn=32
  • phase3The Effects of Psilocybin on Self-Focus and Self-Related Processing in Major Depressive Disorderrecruitingn=20
  • phase2A Study of Psilocybin for Major Depressive Disorder (MDD)completedn=347
  • EP1Exploratory Study of Low Dose Psilocybinwithdrawn
  • phase1A Study Assessing Brain Activity, Safety, Tolerability, and Pharmacokinetics Following Multiple Doses of MLS101 (Psilocybin) in Healthy Volunteerscompletedn=20

News(10)

  • Serious adverse events mar robust efficacy data for Helus’ psychedelic in major depression
    Helus Pharma's psilocin-based HLP003 significantly reduced symptoms of major depressive disorder in the adjuvant setting in a Phase 3 trial but was tripped up in the stock market by three serious a…
    biospace · 1d ago
  • Helus' chemically modified psychedelic hits key goals in phase 3 depression trial
    Helus Pharma's oral chemically modified version of psilocybin hit the key goals of a phase 3 study as an adjunctive treatment in major depressive disorder.
    fiercebiotech · 1d ago
  • HHS pumps up to $25M into ibogaine, other psychotropic drugs on Veteran’s Day
    Ibogaine, which operates via a “matrix pharmacology,” has long been a focus of Health Secretary Robert F. Kennedy Jr. and the Trump administration.
    biospace · 4d ago
  • FDA’s commissioner voucher program reportedly shuttered ahead of Senate vote on Overton
    In advance of a Senate vote on Heidi Overton as the next FDA commissioner, the agency has shelved the Commissioner's National Priority Voucher program introduced by former leader Marty Makary, Reut…
    biospace · 5d ago
  • ARPA-H bets $4.9 million on ibogaine for PTSD treatment in veterans
    The U.S. department of health and human services announced a $4.9 million bet to advance the development of ibogaine for post-traumatic stress disorder (PTSD).
    fiercebiotech · 5d ago
  • AstraZeneca buys vaccine startup; FDA issues GLP-1 safety warning
    The deal gives AstraZeneca a simpler way to make conjugate vaccines. Elsewhere, a psychedelic depression drug was submitted to the FDA and an autoimmune disease-focused biotech’s shares collapsed.
    biopharma_dive · 6d ago
  • Update: Compass submits psilocybin depression drug for approval after stock wobbles
    Compass Pathways has completed an FDA filing for COMP360, with an expected launch in the first half of next year. The update follows a reported regulatory submission for Usona Institute’s own psilo…
    biospace · 8d ago
  • J&J-backed Delix drums up $100M series C for non-hallucinatory psychedelic for depression
    Delix Therapeutics has raised $100 million in a series C round backed by the likes of Johnson & Johnson to advance a phase 2-ready non-hallucinatory psychedelic therapy for depression.
    fiercebiotech · 8d ago
  • STAT+: Pharma critic Bernie Sanders is set to hold major sway over FDA funding bill
    Sanders could use his role in crafting the FDA funding bill to push for reforms.
    stat · 13d ago
  • STAT+: CVS Health to split, reversing years of deal-making to combine pharmacies and insurance
    CVS Health’s decision to split comes amid federal and state scrutiny over vertical integration.
    stat · 13d ago
view all news mentions →
generic
psilocybin
MOA
Serotonin 2a (5-HT2a) receptor agonist
indication
Treatment Resistant Depression
phase
phase_3
Data sources
ClinicalTrials.gov · OpenTargets
last refreshed 47m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?